The International Trade Commission is a hot forum for patent disputes, but it's almost never used by pharmaceutical companies, whose IP cases typically involve specialized fights between brand-name and generic drug makers. But now, Eli Lilly has turned to the ITC in a novel strategy to beat back generic competition.
March 18, 2011 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
The International Trade Commission is a hot forum for patent disputes, but it’s almost never used by pharmaceutical companies, whose IP cases typically involve specialized fights between brand-name and generic drug makers.
That may be changing. In a novel strategy to beat back generic competition to its blockbuster cancer drug Gemzar, Eli Lilly and Co. has turned to the ITC.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
